Full View

Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5

RF Kushner, S Calanna, M Davies, D Dicker… - …, 2020 - Wiley Online Library
Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …
被引用次数：256 相关文章

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushner, S Calanna, M Davies, D Dicker… - 2020 - pubmed.ncbi.nlm.nih.gov
Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushner, S Calanna, M Davies… - …, 2020 - utsouthwestern.elsevierpure.com
Objective: The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …
[PDF] le.ac.uk

[PDF][PDF] Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushner, S Calanna, M Davies, D Dicker… - 2020 - figshare.le.ac.uk
Objective: The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Semaglutide 2.4 mg for the treatment of obesity: Key elements of the STEP trials 1 to 5

RF Kushner - 2021 - sciencehub.novonordisk.com
of the original article ‘Semaglutide 2.4 mg for the treatment of obesity: Key elements of the
STEP trials 1 to 5’ Page 1 © 2021 Novo Nordisk A/S; Further reproduction and distribution is …

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.

RF Kushner, S Calanna, M Davies, D Dicker… - Obesity (Silver Spring …, 2020 - europepmc.org
Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5.

RF Kushner, S Calanna, M Davies, D Dicker… - 2020 - cabidigitallibrary.org
The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushner, S Calanna, M Davies, D Dicker… - Obesity, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> The obesity epidemic is a public
health concern, warranting further research into pharmacological treatments for weight …
[HTML] nih.gov

[HTML][HTML] Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushner, S Calanna, M Davies… - Obesity (Silver Spring …, 2020 - ncbi.nlm.nih.gov
Objective The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …
[PDF] sochob.cl

[PDF][PDF] Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

RF Kushner, S Calanna, M Davies, D Dicker… - 2020 - sochob.cl
Objective: The obesity epidemic is a public health concern, warranting further research into
pharmacological treatments for weight management (WM) as an adjunct to lifestyle …